Erschienen in:
01.06.2012 | Position Statement
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
verfasst von:
S. E. Inzucchi, R. M. Bergenstal, J. B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A. L. Peters, A. Tsapas, R. Wender, D. R. Matthews
Erschienen in:
Diabetologia
|
Ausgabe 6/2012
Einloggen, um Zugang zu erhalten
Excerpt
Glycaemic management in type 2 diabetes mellitus has become increasingly complex and, to some extent, controversial, with a widening array of pharmacological agents now available [
1‐
5], mounting concerns about their potential adverse effects and new uncertainties regarding the benefits of intensive glycaemic control on macrovascular complications [
6‐
9]. Many clinicians are therefore perplexed as to the optimal strategies for their patients. As a consequence, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) convened a joint task force to examine the evidence and develop recommendations for anti-hyperglycaemic therapy in non-pregnant adults with type 2 diabetes. Several guideline documents have been developed by members of these two organisations [
10] and by other societies and federations [
2,
11‐
15]. However, an update was deemed necessary because of contemporary information on the benefits/risks of glycaemic control, recent evidence concerning efficacy and safety of several new drug classes [
16,
17], the withdrawal/restriction of others and increasing calls for a move towards more patient-centred care [
18,
19]. …